Ciltacabtagene autoleucel for the treatment of multiple myeloma [0.03%]
治疗多发性骨髓瘤的Ciltacabtagene Autoleucel疗法
Sarah A Holstein
Sarah A Holstein
While treatment options for multiple myeloma (MM) are continuing to expand, this disease remains one characterized by requiring multiple lines of therapy, with generally decreasing effectiveness of each subsequent line. The development of B...
Xuan-Yu Chen,Yi-Dong Li,Yuhao Xie et al.
Xuan-Yu Chen et al.
Melanoma is a highly lethal type of skin cancer. Although an early diagnosis, in combination with surgery for nonmetastatic melanomas, significantly increases the probability of survival, there are no efficacious treatments for metastatic m...
Rusi Chen,Luca Ielasi,Alma di Carlo et al.
Rusi Chen et al.
Hepatocellular carcinoma (HCC) is a global healthcare problem, with a high prevalence in nonindustrialized countries and a rising incidence in industrialized countries. Sorafenib demonstrated its efficacy as the first therapeutic agent for ...
Cyriac Manjaly,Jeremy Martinez,John Barbieri et al.
Cyriac Manjaly et al.
Clascoterone is a novel topical antiandrogen medication approved for the treatment of acne. Conventional oral antiandrogen treatments targeting acne such as combined oral contraceptives and spironolactone exert systemic hormonal effects whi...
Martina Messina,Paul Gissen
Martina Messina
Metachromatic leukodystrophy (MLD) is a rare autosomal recessive disorder of sphingolipid metabolism, due to a deficiency of the enzyme arylsulfatase A (ARSA). The main clinical signs of the disease are secondary to central and peripheral n...
Michael F Loncharich,Ian Robertson
Michael F Loncharich
Systemic lupus erythematosus is a complex autoimmune disease with variable disease presentation and progression. Hydroxychloroquine and corticosteroids are first-line therapies. Disease severity and organ system involvement guide escalation...
COVID-19 vaccination in patients with multiple sclerosis receiving disease-modifying therapies: pragmatic issues [0.03%]
多重硬化症患者在接受疾病修饰治疗时的COVID-19疫苗接种：实用问题
Ioan-Alexandru Chirap-Mitulschi,Constantin Ghimus,Andreea Raluca Chirap-Mitulschi et al.
Ioan-Alexandru Chirap-Mitulschi et al.
The SARS-COV-2 pandemic has been a global public health problem since 2019, with over 400 million reported cases, 6 million deaths, and significant economic and social damage. Overlapping SARS-CoV-2 infection in patients with chronic diseas...
Tezepelumab for asthma [0.03%]
特塞普单抗治疗哮喘
Santi Nolasco,Corrado Pelaia,Giulia Scioscia et al.
Santi Nolasco et al.
The epithelium, once simply considered a protective barrier against harmful agents, has in recent times gained considerable relevance as an entity that can promote and regulate inflammatory processes through the production of cytokines, nam...
Dong-Hua Yang,Qisi Lu,Zhaohui Zhu et al.
Dong-Hua Yang et al.
Myelofibrosis is a rare progressive cancer of the bone marrow that disrupts the normal production of healthy blood cells, leading to bone marrow failure. Patients with myelofibrosis and severe thrombocytopenia (platelet count below 50 × 10...
Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection [0.03%]
卡博特格拉韦：一种新型的与rilpivirine结合用于治疗HIV感染的长效注射方案的HIV整合酶抑制剂
John D Zeuli,Christina G Rivera,Bradley L Smith et al.
John D Zeuli et al.
Cabotegravir, a novel HIV integrase inhibitor, shares structural similarity with dolutegravir and bictegravir. Its oral half-life is 32 hours, but cabotegravir nanosuspension for intramuscular injection yields half-lives ranging from 25 to ...